Medscape is available in 5 Language Editions – Choose your Edition here.


Ophthalmologic Manifestations of Pseudoxanthoma Elasticum Clinical Presentation

  • Author: Andrew A Dahl, MD, FACS; Chief Editor: Hampton Roy, Sr, MD  more...
Updated: May 09, 2016


The syndrome of pseudoxanthoma elasticum is a disorder of connective tissue characterized by multisystem involvement. Clinically, involvement of the eyes, skin, central nervous system, heart, and GI system may be present to variable extents, as well as peripheral arterial disease. The stretchable skin, cardiac changes, and choroidal breaks are signs that pseudoxanthoma elasticum shares with variants of Ehlers-Danlos syndrome.


It has been reported that 87% of patients with pseudoxanthoma elasticum have associated angioid streaks (AS). Angioid streaks appear as cracks deep to the retinal vascular architecture and originate in a ringlike fashion in the peripapillary area and radiate from the optic nerve head coursing in all directions. Angioid streaks are visible as dark red-to-brown bands and are variable in their pigmentation. These brown bands represent breaks in the thickened and calcified Bruch membrane. The Bruch membrane is a collagen- and elastin-containing membrane between the retina and the choroid.

Angioid streaks may progress slowly or remain stationary for years. Angioid streaks almost always occur bilaterally.

During fluorescein angiography, angioid streaks may show increased fluorescence in the early phase resulting from atrophy of the retinal pigment epithelium overlying an intact choriocapillaris.

Defects in the Bruch membrane may predispose to choroidal neovascular ingrowth, which can result in subretinal hemorrhage and ultimately disciform degeneration.

Macular involvement with loss of vision usually appears after age 40 years and may be due to retinal pigment epithelium atrophy or choroidal neovascular membrane. Some choroidal neovascular membranes are amenable to treatment with laser photocoagulation[1] (however, visual results are disappointing). Visual field loss secondary to optic disk drusen has been reported in patients with pseudoxanthoma elasticum who have angioid streaks.

In addition to angioid streaks, other fundus lesions, including optic disc drusen, macular pattern dystrophy, crystalline bodies, and midperipheral “comet-tail” atrophic spots have been described in pseudoxanthoma elasticum.

Peau d'orange has been described as diffuse mottling of the retinal pigment epithelium in an area temporal to the macula in patients with pseudoxanthoma elasticum. This may occur with or without the presence of angioid streaks.

Choroidal ruptures and retinal hemorrhages have been reported in patients with pseudoxanthoma elasticum as a result of minor ocular trauma.

Irregularly shaped lesions with variable depigmentation have been observed in the periphery of patients with pseudoxanthoma elasticum. This may represent isolated areas of peripheral dehiscences in the Bruch membrane.

Keratoconus is frequently seen in patients with pseudoxanthoma elasticum. This is indistinguishable from other cases of keratoconus. Presenting symptoms include fluctuating or blurred vision that is not correctable by spectacles or hydrophilic contact lenses.


The characteristic skin changes in pseudoxanthoma elasticum consist of yellow plaques or xanthoma-like papules in the flexural areas of the body. This change has been likened to plucked chicken skin. The skin lesions typically are distributed in the intertriginous areas of the body.

The most commonly affected areas of the body are as follows: the folds of the skin at the sides of the neck, the flexural regions of the extremities, the axilla, the popliteal and antecubital fossa, the creases of the groin, and the periumbilical region of the abdominal wall.

The skin changes usually are noted between the second and fourth decades of life. Late in the disease, the skin frequently becomes thickened and hangs in loose redundant folds.

Central nervous system

Neurologic complications in patients with pseudoxanthoma elasticum have been reported in the literature. These include multiple lacunar infarcts, aneurysms, cerebrovascular insufficiency, subarachnoid and intracerebral hemorrhages, progressive intellectual deterioration, and psychic and mental disturbance.

Seizures occur more frequently than in the general population. Subarachnoid hemorrhage is a potential cause of death.

Cardiovascular findings

Cardiovascular involvement in patients with pseudoxanthoma elasticum occurs at an early age, but it is rarely a presenting manifestation.

Angina pectoris is a common finding, but myocardial infarction is rare. Aneurysms may occur in any region of the cardiovascular system.

GI system

Upper GI tract hemorrhage can be a serious complication of pseudoxanthoma elasticum. GI hemorrhage has been reported as early as age 6.5 years.

GI hemorrhage is a fairly common occurrence and usually occurs early in the course of the disease, when the cutaneous and ocular changes are minimal. It may be life threatening and can occur in as many as 15% of patients. The GI hemorrhage may be secondary to the degeneration of the elastic tissue of arteries of the gastric wall.

Peripheral arterial system

Changes in the vascular system are characterized by premature calcification of the peripheral arteries of the extremities and can be detected by x-ray film.

Atherosclerotic changes cause peripheral vascular disease, which results in weak or absent peripheral pulses and claudication of the lower extremities.

Hypertension is 3 times more common in patients with this condition than in the general population and occurs at an early age.



Yellow xanthomalike plaques are present in the flexural areas of the body. The sides of the neck are the most common sites.

Angioid streaks are nearly always bilateral and usually appear in the second decade of life. Angioid streaks are brown streaks forming an incomplete ring around the optic nerve and radiating from the disk toward the equator of the eye. Angioid streaks may lead to macular degeneration, disciform scarring, and hemorrhagic maculopathy via the degenerative process of choroidal neovascularization (ie, abnormal choroidal vessels gaining access to the subretinal space through breaks in the Bruch membrane).

Optic nerve drusen

Corneal findings in patients with keratoconus include the topographic findings typically associated with keratoconus.

Diffuse mottling of the retinal pigment epithelium in the temporal periphery resembles the appearance of the skin of an orange (peau d'orange).

Peripheral arterial pulsations may be absent in both upper and lower extremities.

Hypertension may result from the involvement of the renal arteries and may occur in the adolescent age group.



Pseudoxanthoma elasticum is an inherited systemic disease characterized by abnormal amounts of elastic tissue that have an unusual propensity to become calcified.


Pseudoxanthoma elasticum is primarily inherited in an autosomal-recessive manner, which means both copies of the gene in each cell have mutations. Mutations in the ABCC6 gene cause pseudoxanthoma elasticum. To date, more than 300 distinct mutations have been identified in pseudoxanthoma elasticum. Mutations in the ABCC6 gene lead to an absent or nonfunctional MRP6 protein, an acronym for multidrug resistance-associated protein 6 (MRP6, also known as the ABCC6 protein).[2, 3]

Autosomal-dominant inheritance is less common.

Contributor Information and Disclosures

Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Andrew A Dahl, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society

Disclosure: Nothing to disclose.


Sherif M El-Harazi, MD, MPH Private Practice in Ophthalmology

Sherif M El-Harazi, MD, MPH is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, International Society of Refractive Surgery

Disclosure: Nothing to disclose.

Diego Calonje, MD Consulting Staff, Department of Ophthalmology, Private Practice

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Steve Charles, MD Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, Club Jules Gonin

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

V Al Pakalnis, MD, PhD Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, South Carolina Medical Association

Disclosure: Nothing to disclose.

  1. Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol. 1993 Oct 15. 116(4):414-23. [Medline].

  2. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet. 2000 Jun. 25(2):228-31. [Medline].

  3. Struk B, Neldner KH, Rao VS, St Jean P, Lindpaintner K. Mapping of both autosomal recessive and dominant variants of pseudoxanthoma elasticum to chromosome 16p13.1. Hum Mol Genet. 1997 Oct. 6(11):1823-8. [Medline].

  4. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009 Dec. 50(12):5913-8. [Medline].

  5. Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HP. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol. 2008 Apr. 92(4):483-7. [Medline].

  6. Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol. 2009 Oct. 148(4):584-590.e2. [Medline].

  7. Schoenberger SD, Agarwal A. Geographic chorioretinal atrophy in pseudoxanthoma elasticum. Am J Ophthalmol. 2013 Oct. 156(4):715-23. [Medline].

  8. Agarwal A, Patel P, Adkins T, Gass JD. Spectrum of pattern dystrophy in pseudoxanthoma elasticum. Arch Ophthalmol. 2005 Jul. 123(7):923-8. [Medline].

  9. Albert DM, et al. Pseudoxanthoma elasticum (PXE)-angioid streaks/systemic associations. Principles and Practice of Ophthalmology Clinical Practice. Philadelphia: WB Saunders; 1994.

  10. Audo I, Vanakker OM, Smith A, et al. Pseudoxanthoma elasticum with generalized retinal dysfunction, a common finding?. Invest Ophthalmol Vis Sci. 2007 Sep. 48(9):4250-6. [Medline].

  11. Chung AK, Gauba V, Ghanchi FD. Photodynamic therapy (PDT) using verteporfin for juxtafoveal choroidal neovascularisation (CNV) in angioid streaks (AS) associated with pseudoxanthoma elasticum: 40 months results. Eye (Lond). 2006 May. 20(5):629-31. [Medline].

  12. Clarkson JG, Altman RD. Angioid streaks. Surv Ophthalmol. 1982 Mar-Apr. 26(5):235-46. [Medline].

  13. Coleman K, Ross MH, Mc Cabe M, Coleman R, Mooney D. Disk drusen and angioid streaks in pseudoxanthoma elasticum. Am J Ophthalmol. 1991 Aug 15. 112(2):166-70. [Medline].

  14. Connor PJ Jr, et al. Pseudo-xanthoma elasticum and angioid streaks: a review of 106 cases. Am J Med. 1961. 30:537-43.

  15. Engelman MW, Fliegelman MT. Pseudoxanthoma elasticum. Cutis. 1978 Jun. 21(6):837-40. [Medline].

  16. Finger RP, Charbel Issa P, Ladewig MS, et al. Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches. Surv Ophthalmol. 2009 Mar-Apr. 54(2):272-85. [Medline].

  17. Goodman RM, Smith EW, Paton D, Bergman RA, Siegel CL, Ottesen OE. Pseudoxanthoma Elasticum: A Clinical And Histopathological Study. Medicine (Baltimore). 1963 Sep. 42:297-334. [Medline].

  18. Grand MG, Isserman MJ, Miller CW. Angioid streaks associated with pseudoxanthoma elasticum in a 13-year-old patient. Ophthalmology. 1987 Feb. 94(2):197-200. [Medline].

  19. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009 May-Jun. 54(3):372-400. [Medline].

  20. Iqbal A, Alter M, Lee SH. Pseudoxanthoma elasticum: a review of neurological complications. Ann Neurol. 1978 Jul. 4(1):18-20. [Medline].

  21. Martinez-Hernandez A, Huffer WE. Pseudoxanthoma elasticum: dermal polyanions and the mineralization of elastic fibers. Lab Invest. 1974 Aug. 31(2):181-6. [Medline].

  22. Sawa M, Ober MD, Freund KB, Spaide RF. Fundus autofluorescence in patients with pseudoxanthoma elasticum. Ophthalmology. 2006 May. 113(5):814-20.e2. [Medline].

  23. Marconi B, Bobyr I, Campanati A, Molinelli E, Consales V, Brisigotti V, et al. Pseudoxanthoma elasticum and skin: Clinical manifestations, histopathology, pathomechanism, perspectives of treatment. Intractable Rare Dis Res. 2015 Aug. 4 (3):113-22. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.